Best of ADA China 2026 走进ADA直播间｜早期强化引领T2DM管理变革，口服GLP-1RA开启代谢治疗新时代

参考文献

[1]. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12.

[2]. Kristina Secnik Boye, et al. Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results after Two Years of Treatment in SURPASS-EARLY. 2026 ADA. 1667-P

[3]. Kristina Secnik Boye, et al. Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial. 2026 ADA. 1668-P

[4]. Julio Rosenstock, et al. Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3. 2026 ADA.

[5]. Julio Rosenstock, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med . 2025 Sep 18;393(11):1065-1076. doi: 10.1056/NEJMoa2505669 Epub 2025 Jun 21.

[6]. Francesco Giorgino, et al. Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5. 2026 ADA.1253-OR

[7]. Michelle Welch,et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet . 2026 Jun 8:S0140-6736(26)00800-7. doi: 10.1016/S0140-6736(26)00800-7 Online ahead of print.

[8]. Sean Wharton,et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med . 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774 Epub 2025 Sep 16.